1. The Parkinson's Disease Psychosis Journal Club

3. Program Goals

4. Atypical Antipsychotics and PD Psychosis

5. Antipsychotic Efficacy: Quetiapine

6. Antipsychotic Efficacy: Clozapine

7. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson's Disease Psychosis

8. Increased Mortality With Concomitant Use of Antipsychotics

9. Adverse Events

10. Dementia Studies

11. Clozapine in PDP

12. Long-term Care

13. Caregiver Burden

14. The Malignant Course of "Benign Hallucinations" in Parkinson Disease

15. Are Hallucinations Benign?

16. Progressing Beyond Benign Hallucinations

18. PD and Dementia

19. Polypharmacy in PDP

20. PDP and the Serotonergic System

21. PDP Treatment Guidelines

22. Pimavanserin for Patients With Parkinson’s Disease Psychosis: A Randomised, Placebo-controlled Phase 3 Trial

23. Pimavanserin for PDP: Adverse Events

24. SAPS-PD

25. Pimavanserin for PDP: Efficacy

26. Reductions in Caregiver Burden

27. Run-in and Placebo Effect

28. PDP Prevalence

29. Identifying PDP Psychosis

30. Implications of Effective PDP Treatments

31. Conclusions

32. Abbreviations